etoposide/krūties vėžys

Nuoroda įrašoma į mainų sritį

Straipsniai Klinikiniai tyrimai Patentai

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 722 rezultatus

Chronic oral etoposide in advanced breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Chronic oral etoposide has shown activity in some metastatic refractory tumors. To test its activity in previously treated metastatic breast cancer patients, we started a study in 18 consecutive patients given etoposide orally at 50 mg/m2 daily for 21 days. A partial response was observed in 4 of 18

Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We report a high risk of therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) in patients receiving oral administration of etoposide for recurrent breast cancer. We examined 119 patients with recurrent disease. Patients were initially treated with anthracyclines,

[Efficacy of etoposide in bone metastasis of breast cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We have used ADM, MMC, CDDP and other drugs for a case of bone metastasis of breast cancer, but the bone destruction was advanced and she could not walk. We have also used etoposide, a new chemotherapeutic drug, for the same case. Two months later bone sclerosis was seen by X-ray film and pain

High-dose etoposide in treatment of metastatic breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

High-dose etoposide (1,500-2,500 mg/m2) was used for the treatment of 23 previously treated patients with advanced breast cancer. Six of 23 (26%) showed objective regression with a median duration of response of 5 months. Responses were seen at all sites apart from bone. Response was related to dose

Doxorubicin and etoposide in the treatment of advanced measurable breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Nineteen evaluable patients with advanced breast cancer were treated with a combination of doxorubicin and etoposide. Patients had measurable disease, received only mild pretreatment and most had good general conditions at start of therapy. Strict criteria for dose adjustments according to nadir

DNA repair in Etoposide-induced DNA damage in lymphocytes of breast cancer patients and healthy women.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The present study evaluated the basal DNA damage and the cellular response to this damage induced by in vitro administration of Etoposide in lymphocytes donated by twenty untreated breast cancer (BC) patients and twenty age-matched healthy women. Micronucleus (MN) and alkaline Comet assays were

Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The pharmacokinetics and pharmacodynamics of prolonged oral etoposide chemotherapy were investigated in 15 women with metastatic breast cancer who received oral etoposide 100 mg as a single daily dose for up to 15 days. There was considerable interpatient variability in the day 1 pharmacokinetic

Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Carboplatin is used in many kind of tumors with similar results to cisplatin but without the same toxicity. We decided to use it, in combination with etoposide, for metastatic breast cancer. Eighteen women with advanced breast disease entered this phase II study. Each of them received, every 28

Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To determine the efficacy and toxicity of the carboplatin and oral etoposide combination in patients with advanced breast cancer previously treated with anthracyclines. METHODS Twenty-seven patients were treated with a maximum of 6 cycles of carboplatin (300 mg/m2) and etoposide (200

Novel Etoposide Analogue Modulates Expression of Angiogenesis Associated microRNAs and Regulates Cell Proliferation by Targeting STAT3 in Breast Cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Tumor microenvironment play role in angiogenesis and carcinogenesis. Etoposide, a known topoisomerase II inhibitor induces DNA damage resulting in cell cycle arrest. We developed a novel Etoposide analogue, Quinazolino-4β-amidopodophyllotoxin (C-10) that show better efficacy in regulating cell

Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The object of the study was to evaluate the effectiveness of ifosfamide/etoposide and mesna therapy in advanced breast cancer. A total of 44 patients with breast cancer were included in the trial. Eligibility criteria included measurable, refractory disease; prior anthracycline therapy (or its

A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Macrophage inflammatory protein-1alpha (MIP-1alpha) is a chemokine that can inhibit the cell cycle progression of both primitive haemopoietic and epidermal progenitor cells. This property could potentially be exploited to attenuate both the myelosuppressive effects of chemotherapy as well as

Combination chemotherapy with oral etoposide plus intravenous cyclophosphamide in liver metastases of breast cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Sixteen patients with hepatic metastases of histologically documented breast cancer were treated with etoposide (VP 16-213) and cyclophosphamide. Previously, 6 had shown relapse in the liver after adjuvant chemotherapy, 2 had failed to respond to another chemotherapy combination, and 8 had never

Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We have recently treated 66 women with breast cancer with escalating doses of ifosfamide, carboplatin, and etoposide (ICE) followed by autologous stem cell rescue (ASCR). Patients received ifosfamide (6000-24,000 mg m-2), carboplatin (1200-2100 mg m-2), and etoposide (1800-3000 mg m-2) divided over

Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE This phase II study was conducted to evaluate the efficacy and tolerability of vinorelbine (navelbine) and oral VP-16 (etoposide) in pretreated metastatic breast cancer (MBC) patients. METHODS Twenty-two female patients with therapy-resistant metastatic breast cancer were treated with

Ankstesnis
1
2
3
4
5
6
...
48
49
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais